583 related articles for article (PubMed ID: 33996259)
1. m
Xu F; Huang X; Li Y; Chen Y; Lin L
Mol Ther Nucleic Acids; 2021 Jun; 24():780-791. PubMed ID: 33996259
[TBL] [Abstract][Full Text] [Related]
2. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
3. Prognostic Value of Genomic Instability of m
Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
[No Abstract] [Full Text] [Related]
4. Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.
Zhang H; Liu M; Yang Z; Du G; Yu B; Gui Y; Cao L; Li X; Tan B
Sci Rep; 2022 Jul; 12(1):12785. PubMed ID: 35896612
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial Homeostasis-Related lncRNAs are Potential Biomarkers for Predicting Prognosis and Immune Response in Lung Adenocarcinoma.
Peng B; Lou H; Chen C; Wang L; Li H; Lu T; Na R; Xu R; Xin T; Yao L; Xu H; Wang K; Liu X; Zhang L
Front Genet; 2022; 13():870302. PubMed ID: 35769997
[TBL] [Abstract][Full Text] [Related]
8. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
9. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
10. An N
Song D; Tian Y; Luo J; Shao G; Zheng J
Ann Transl Med; 2022 Apr; 10(8):464. PubMed ID: 35571429
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma.
Wu S; Tu Q; Yuan H; Wu Z; Yang Y; Chen C; Huang C
Biochem Genet; 2023 Nov; ():. PubMed ID: 37999876
[TBL] [Abstract][Full Text] [Related]
12. Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma.
Wang H; Cui J; Yu J; Huang J; Li M
Front Genet; 2022; 13():855940. PubMed ID: 35464865
[TBL] [Abstract][Full Text] [Related]
13. Construction of a lung adenocarcinoma prognostic model based on N6-methyl-adenosine-related long noncoding RNA and screening of potential drugs based on this model.
Hou Q; Zhong Y; Liu L; Wu L; Liu J
Anticancer Drugs; 2022 Apr; 33(4):371-383. PubMed ID: 35213857
[TBL] [Abstract][Full Text] [Related]
14. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
15. Comprehensive analysis of m6A modification patterns and m6A-related lncRNAs as potential biomarkers in lung adenocarcinoma.
Wang S; Gu X; Xu D; Liu B; Qin K; Yuan X
Environ Toxicol; 2024 Apr; 39(4):2285-2303. PubMed ID: 38148718
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
[TBL] [Abstract][Full Text] [Related]
17. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.
Li Z; Liu Y; Yi H; Cai T; Wei Y
Front Genet; 2022; 13():947747. PubMed ID: 36246627
[TBL] [Abstract][Full Text] [Related]
18. Analysis of M6A associated lncRNAs in prognosis and immune response of NSCLC patients.
Lin J; Gu XL; Li CL; Wang ZM; Wang ZF; Wu RP; Song Y; Wu Y; Liu HB
Am J Transl Res; 2022; 14(12):8457-8472. PubMed ID: 36628246
[TBL] [Abstract][Full Text] [Related]
19. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma.
Lu L; Liu LP; Zhao QQ; Gui R; Zhao QY
Front Oncol; 2021; 11():675545. PubMed ID: 34249715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
